The Castilian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) by de Inocencio, Jaime et al.
Vol.:(0123456789) 
Rheumatology International (2018) 38 (Suppl 1):S91–S98 
https://doi.org/10.1007/s00296-018-3976-6
VALIDATION STUDIES
The Castilian Spanish version of the Juvenile Arthritis 
Multidimensional Assessment Report (JAMAR)
Jaime de Inocencio1,2 · Jordi Anton3 · Inmaculada Calvo Penades4 · Pablo Mesa del Castillo Bermejo5 · 
Rosa Alcobendas6 · Alina Lucica Boteanu7 · Rosa Bou3 · Estibaliz Iglesias3 · María Isabel González Fernandez4 · 
Berta López Montesinos4 · Palmira Santin3 · Paula Alcañiz Rodriguez5 · Maria Jose Lorente Sanchez5 · 
Alessandro Consolaro8,9 · Francesca Bovis8 · Nicolino Ruperto8 · For the Paediatric Rheumatology International 
Trials Organisation (PRINTO)
Received: 22 December 2017 / Accepted: 11 January 2018
© The Author(s) 2018. This article is an open access publication
Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that 
enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results 
of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Castilian Spanish lan-
guage. The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre 
was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients 
seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation 
phase explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, floor/ceiling 
effects, internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability and construct validity (convergent 
and discriminant validity). A total of 526 JIA patients (8.6% systemic, 49.4% oligoarticular, 18.2% RF negative polyarthritis, 
23.8% other categories) and 78 healthy children, were enrolled in six centres. The JAMAR components discriminated well 
healthy subjects from JIA patients. All JAMAR components revealed good psychometric performances. In conclusion, the 
Castilian Spanish version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use both 
in routine clinical practise and clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Castilian Spanish parent, child/adult ver-
sion of the Juvenile Arthritis Multidimensional Assessment 
Report (JAMAR) [1] in patients with juvenile idiopathic 
arthritis (JIA). The JAMAR assesses the most relevant 
parent/patient reported outcomes in JIA, including overall 
well-being, functional status, health related quality of life 
(HRQoL), pain, morning stiffness, disease activity/status/
course, articular and extra-articular involvement, drug-
related side effects/compliance and satisfaction with illness 
outcome.
This project was part of a larger multinational study 
conducted by the Paediatric Rheumatology International 
Trials Organisation (PRINTO) [2] aimed to evaluate the 
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Epidemiology, Outcome and Treatment of Childhood 
Arthritis (EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Castilian Spanish language.
Materials and methods
The methodology employed has been described in detail 
in the introductory paper of the supplement [4]. In brief, 
it was a cross-sectional study of JIA children, classified 
according to the ILAR criteria [5, 6] and enrolled from 
January 2012 to January 2016. Children were recruited 
after Ethics Committee approval and consent from at least 
one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. Assessment of physical function (PF) using 15-items 
in which the ability of the child to perform each task is 
scored as follows: 0 = without difficulty, 1 = with some 
difficulty, 2 = with much difficulty, 3 = unable to do and 
not applicable if it was not possible to answer the ques-
tion or the patient was unable to perform the task due 
to their young age or to reasons other than JIA. The 
total PF score ranges from 0 to 45 and has 3 com-
ponents: PF-lower limbs (PF-LL); PF-hand and wrist 
(PF-HW) and PF-upper segment (PF-US) each scor-
ing from 0 to 15 [7]. Higher scores indicating higher 
degree of disability. [8–10].
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11].
 3. Assessment of the presence of joint pain or swelling 
(present/absent for each joint).
 4. Assessment of morning stiffness (present/absent).
 5. Assessment of extra-articular symptoms (fever and 
rash) (present/absent).
 6. Rating of the level of disease activity on a 21-circle 
VAS.
 7. Rating of disease status at the time of the visit (cat-
egorical scale).
 8. Rating of disease course from previous visit (categori-
cal scale).
 9. Checklist of the medications the patient is taking (list 
of choices).
 10. Checklist of side effects of medications.
 11. Report of difficulties with medication administration 
(list of items).
 12. Report of school/university/work problems caused by 
the disease (list of items).
 13. Assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) subscales (5 
items each) and total a score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14].
 14. Rating of the patient’s overall well-being on a 21-num-
bered circle VAS.
 15. A question about satisfaction with the outcome of the 
illness (Yes/No) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-cultural adapted in 
a similar language (i.e., Spanish in South American coun-
tries), only the probe technique was performed. Reading 
comprehension and understanding of the translated ques-
tionnaires were tested in a probe sample of ten JIA parents 
and ten patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy children 
and their parents.
The statistical validation phase explored the descriptive 
statistics and the psychometric issues [16]. In particular, we 
evaluated the following validity components: the first Likert 
assumption [mean and standard deviation (SD) equivalence]; 
the second Likert assumption or equal items-scale correla-
tions (Pearson r: all items within a scale should contribute 
equally to the total score); third Likert assumption (item 
internal consistency or linearity for which each item of a 
scale should be linearly related to the total score that is 
90% of the items should have Pearson r ≥ 0.4); floor/ceiling 
effects (frequency of items at lower and higher extremes of 
the scales, respectively); internal consistency, measured by 
the Cronbach’s alpha, interscale correlation (the correlation 
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between two scales should be lower than their reliability 
coefficients, as measured by Cronbach’s alpha); test–retest 
reliability or intraclass correlation coefficient (reproducibil-
ity of the JAMAR repeated after 1 or 2 weeks); and construct 
validity in its two components: the convergent or external 
validity which examines the correlation of the JAMAR sub-
scales with the six JIA core set variables, with the addition 
of the parent assessment of disease activity and pain by the 
Spearman’s correlation coefficients (r) [17] and the discri-
minant validity, which assesses whether the JAMAR dis-
criminates between the different JIA categories and healthy 
children [18].
Quantitative data were reported as medians with 1st and 
3rd quartiles and categorical data as absolute frequencies 
and percentages.
The complete Castilian Spanish parent and patient ver-
sions of the JAMAR are available upon request to PRINTO.
Results
Cross‑cultural adaptation
The Castilian Spanish JAMAR was fully cross-culturally 
adapted from the standard English version with three for-
ward and three backward translations with a concordance 
for 116/123 (94.3%) translations lines for the parent version 
and 113/120 (94.2%) lines for the child version.
All 123 lines of the parent version of the JAMAR 
were understood by at least 80% of the 10 parents tested 
(median = 100%; range 80–100%). All the 120 lines of the 
patient version of the JAMAR were understood by at least 
80% of the children (median = 100%; range 80–100%). The 
text of the parent and patient JAMAR were left unmodified 
after the probe technique.
Demographic and clinical characteristics 
of the subjects
A total of 527 JIA patients and 78 healthy children (total of 
605 subjects), were enrolled at six paediatric rheumatology 
centres. One patient did not give the consent to use his/her 
data.
In the remaining 526 JIA subjects, the JIA categories 
were 8.6% with systemic arthritis, 49.4% with oligoarthritis, 
18.2% with RF negative polyarthritis, 1.0% with RF posi-
tive polyarthritis, 5.5% with psoriatic arthritis, 9.5% with 
enthesitis related arthritis and 7.8% with undifferentiated 
arthritis (Table 1).
A total of 593/604 (98.2%) subjects had the parent ver-
sion of the JAMAR completed by a parent (515 from parents 
of JIA patients and 78 from parents of healthy children). The 
JAMAR was completed by 433/593 (73.0%) mothers and 
160/593 (27.0%) fathers. The child version of the JAMAR 
was completed by 301/604 (49.8%) children age 6.1 or older. 
Additionally, patients younger than 7-years-old, capable to 
assess their personal condition and able to read and write, 
were asked to fill in the patient version of the questionnaire.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores [median  (1st–3rd quartile)] obtained for the PF, 
the PhH, the PsH subscales and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The follow-
ing “Results” section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
For all JAMAR items, the median number of missing 
responses were 0.9% (0.4–1.7%). The response pattern for 
both PF and HRQoL was positively skewed toward normal 
functional ability and normal HRQoL. All response choices 
were used for the different HRQoL items, whereas a reduced 
number of response choices was used for PF items 2, 5, 6, 8, 
9, 11, 12, 13 and 14.
The mean and SD of the items within a scale were 
roughly equivalent for the PF and for the HRQoL items 
(data not shown). The median number of items marked as 
not applicable was 6% (2–10%) for the PF and 11% (8–17%) 
for the HRQoL.
Floor and ceiling effect
The median floor effect was 92.4% (90.3–95.1%) for the 
PF items, 70.3% (61.0–72.8%) for the HRQoL PhH items, 
and 71.5% (65.0–75.3%) for the HRQoL PsH items. The 
median ceiling effect was 0% (0–0.2%) for the PF items, 
1.7% (0.6–2.3%) for the HRQoL PhH items, and 1.4% 
(0.8–1.9%) for the HRQoL PsH items. The median floor 
effect was 61.9% for the pain VAS, 57.9% for the disease 
activity VAS and 54.6% for the well-being VAS. The median 
ceiling effect was 0.4% for the pain VAS, 1.0% for the dis-
ease activity VAS and 0.2% for the well-being VAS.
S94 Rheumatology International (2018) 38 (Suppl 1):S91–S98
1 3
Table 1  Descriptive statistics (medians, 1st 3rd quartiles or absolute frequencies and %) for the 526 JIA patients
Data related to the JAMAR refers to the 515 JIA patients and to the 78 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR, Juvenile Arthritis Multidimensional Assessment Report; ESR, erythrocyte sedimentation rate; MD, medical doctor; VAS, visual ana-
logue scale (score 0–10; 0 = no activity, 10 = maximum activity); LOM, limitation of motion; ANA, anti-nuclear antibodies; PF, physical func-
tion (total score ranges from 0 to 45); HRQoL, health related quality of life (total score ranges from 0 to 30); PhH, physical health (total score 
ranges from 0 to 15); PsH, psychosocial health (total score ranges from 0 to 15)
p values refers to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05 **p < 0.001 #p < 0.0001
Systemic Oligoarthritis RF − poly-
arthritis
RF + poly-
arthritis
Psoriatic 
arthritis
Enthesitis 
related 
arthritis
Undifferenti-
ated arthritis
All JIA 
patients
Healthy
N = 45 N = 260 N = 96 N = 5 N = 29 N = 50 N = 41 N = 526 N = 78
Female 23 (51.1%) 205 (78.8%) 74 (77.1%) 5 (100%) 21 (72.4%) 11 (22%) 27 (65.9%) 366 (69.6%)# 46 (59%)
Age at visit 9.3 (5.7–14) 8.5 (5.5–12.1) 8.9 (5.9–12.4) 13.6 (12.7–
16.5)
11.2 
(7.8–14.2)
12.5 
(9.6–15.3)
9.6 (6.4–13.1) 9.3 (6.1–
13.1)#
13 (10–
15.6)#
Age at onset 4 (2.3–8) 2.5 (1.6–4.7) 3 (1.6–5.3) 4.4 (4.4–10.6) 3.3 (1.5–6.5) 8.6 (6.6–10.7) 3.6 (1.8–8.5) 3.2 (1.8–6.7)#
Disease duration 4 (2.5–7.4) 4.9 (1.9–7.7) 4.7 (2.4–7.3) 5.9 (4.2–8.3) 7.4 (3.2–9.9) 3.9 (1.8–6.1) 3.7 (2.4–6.2) 4.7 (2–7.4)
ESR 8 (2–15) 9 (5–15) 7 (4–15) 6 (5–10) 10 (5–25) 7 (5–15) 12 (8–22) 9 (5–15)
MD VAS 
(0–10 cm)
0 (0–1) 0 (0–1) 0 (0–1.5) 2 (2–4) 0 (0–1.5) 0.3 (0–1) 0 (0–2) 0 (0–1)*
No. swollen joints 0 (0–0) 0 (0–0) 0 (0–0) 3 (0–3) 0 (0–1) 0 (0–0) 0 (0–1) 0 (0–0)*
No. joints with 
pain
0 (0–0) 0 (0–0) 0 (0–0) 1 (0–1) 0 (0–1) 0 (0–1) 0 (0–0) 0 (0–0)**
No. joints with 
LOM
0 (0–0) 0 (0–0) 0 (0–1) 0 (0–2) 0 (0–0) 0 (0–0) 0 (0–1) 0 (0–1)
No. active joints 0 (0–1) 0 (0–0) 0 (0–1) 3 (0–3) 0 (0–1) 0 (0–0) 0 (0–2) 0 (0–1)*
Active systemic 
features
2 (4.4%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2/513 (0.4%)
ANA status 0 (0%) 52 (20%) 22 (22.9%) 1 (20%) 8 (27.6%) 3 (6%) 4 (9.8%) 90 (17.1%)
Uveitis 0 (0%) 48/256 
(18.8%)
13/94 (13.8%) 0 (0%) 8/28 (28.6%) 4 (8%) 9 (22%) 82/518 
(15.8%)
PF Total Score 0 (0–1) 0 (0–1) 0 (0–2) 8 (5–14) 0 (0–3) 0 (0–2) 0 (0–1) 0 (0–1)* 0 (0–0)**
Pain VAS 0 (0–0.8) 0 (0–1) 0 (0–1) 3.5 (3–5.5) 1 (0–4) 0.5 (0–3.5) 0 (0–3.8) 0 (0–2)** 0 (0–0)#
Disease Activity 
VAS
0 (0–1.8) 0 (0–1) 0 (0–2) 3.5 (2–4) 0.8 (0–4) 0.5 (0–2.5) 0 (0–2) 0 (0–2)*
Well-being VAS 0 (0–2) 0 (0–1) 0 (0–1.5) 5 (1.5–5.5) 0.5 (0–3) 0.5 (0–3.5) 0.5 (0–3.5) 0 (0–2)*
HRQoL PhH 1 (0–3) 1 (0–3) 1 (0–3) 7 (4–8) 2 (0–4) 2 (0–4) 1 (0–3) 1 (0–3)* 0 (0–0)#
HRQoL PsH 1.5 (0–4) 0 (0–2) 0.5 (0–3) 6 (4–8) 0 (0–3) 1 (0–4) 0 (0–3) 0 (0–3)* 0 (0–0)#
HRQoL Total 
Score
3 (0–7.5) 1 (0–4) 3 (0–5) 13 (8–16) 3 (0–8) 3 (1–8) 2 (0–7) 2 (0–6)* 0 (0–0)#
Pain/swell. in > 1 
joint
14/44 (31.8%) 79/256 
(30.9%)
32/92 (34.8%) 4 (80%) 14 (48.3%) 16/49 (32.7%) 21/40 (52.5%) 180/515 
(35%)*
4 (5.1%)#
Morning stiff-
ness > 15 min
5/44 (11.4%) 18/253 (7.1%) 5/90 (5.6%) 2 (40%) 5 (17.2%) 4/47 (8.5%) 6/40 (15%) 45/508 (8.9%) 1 (1.3%)*
Subjective remis-
sion
9/43 (20.9%) 74/254 
(29.1%)
28/88 (31.8%) 3 (60%) 11/28 (39.3%) 14/47 (29.8%) 15/39 (38.5%) 154/504 
(30.6%)
In treatment 31/44 (70.5%) 170/254 
(66.9%)
82/91 (90.1%) 5 (100%) 25 (86.2%) 38/49 (77.6%) 34/39 (87.2%) 385/511 
(75.3%)*
Reporting side 
effects
6/31 (19.4%) 48/168 
(28.6%)
21/81 (25.9%) 2 (40%) 9/25 (36%) 8/37 (21.6%) 11/33 (33.3%) 105/380 
(27.6%)
Taking medication 
regularly
29/31 (93.5%) 164/169 
(97%)
79/82 (96.3%) 5 (100%) 25/25 (100%) 36/38 (94.7%) 33/34 (97.1%) 371/384 
(96.6%)
With problems 
attending school
4/29 (13.8%) 8/209 (3.8%) 4/67 (6%) 1/3 (33.3%) 3/20 (15%) 2/33 (6.1%) 1/28 (3.6%) 23/389 (5.9%) 0 (0%)*
Satisfied with dis-
ease outcome
40/44 (90.9%) 238/253 
(94.1%)
80/89 (89.9%) 3 (60%) 25 (86.2%) 43/48 (89.6%) 35/40 (87.5%) 464/508 
(91.3%)
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Equal items‑scale correlations (second Likert 
assumption)
Pearson items-scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 80% of the 
PF items, with the exception of PF items 9, 11 and 15, and 
for 90% of the HRQoL items, with the exception of item 1.
Items internal consistency (third Likert assumption)
Pearson items-scale correlations were ≥ 0.4 for 87% of items 
of the PF (except for PF items 11 and 15) and 100% of items 
of the HRQoL.
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR, Juvenile Arthritis Multidimensional Assessment Report; JIA, juvenile idiopathic arthritis; VAS, visual analogue scale; PF, physical 
function; HRQoL, health related quality of life; PhH, physical health; PsH. psychosocial health; PF-LL, PF-lower limbs; PF-HW, PF-hand and 
wrist; PF-US, PF-upper segment
Parent N = 515/593 Child N = 225/301
Missing values (1st–3rd quartiles) 0.9 (0.4–1.7) 0.9 (0.4–1.3)
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 92.4% 94.2%
 HRQoL PhH 70.3% 72.9%
 HRQoL PsH 71.5% 72.9%
 Pain VAS 61.9% 51.1%
 Disease activity VAS 57.9% 51.6%
 Well-being VAS 54.6% 55.1%
Ceiling effect, median
 PF 0.0% 0.0%
 HRQoL PhH 1.7% 0.9%
 HRQoL PsH 1.4% 1.8%
 Pain VAS 0.4% 0.0%
 Disease activity VAS 1.0% 0.4%
 Well-being VAS 0.2% 0.9%
Items with equivalent item-scale correlation 80% for PF, 90% for HRQoL 80% for PF, 80% for HRQoL
Items with items-scale correlation ≥ 0.4 87% for PF, 100% for HRQoL 73% for PF, 100% for HRQoL
Cronbach’s alpha
 PF-LL 0.77 0.79
 PF-HW 0.80 0.74
 PF-US 0.74 0.70
 HRQoL-PhH 0.83 0.85
 HRQoL-PsH 0.82 0.74
Items with item-scale correlation lower than the Cronbach alpha 100% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 0.87 0.26
 HRQoL-PhH 0.03 0.78
 HRQoL-PsH 0.01 0.73
Spearman correlation with JIA core set variables, median
 PF 0.3 0.4
 HRQoL PhH 0.4 0.5
 HRQoL PsH 0.2 0.2
 Pain VAS 0.3 0.3
 Disease activity VAS 0.3 0.3
 Well-being VAS 0.4 0.4
S96 Rheumatology International (2018) 38 (Suppl 1):S91–S98
1 3
Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.77 for PF-LL, 0.80 for PF-HW, 0.74 
for PF-US. Cronbach’s alpha was 0.83 for HRQoL-PhH and 
0.82 for HRQoL-PsH.
Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha.
Test–retest reliability
Reliability was assessed in 20 JIA patients, by re-adminis-
tering both versions (parent and child) of the JAMAR after a 
median of 7 days (7–9 days). The intraclass correlation coef-
ficients (ICC) for the PF total score showed an almost perfect 
reproducibility (ICC = 0.87). The ICC for the HRQoL PhH 
and for the HRQoL PsH scores showed a poor reproducibil-
ity (ICC = 0.03 and ICC = 0.01, respectively).
Convergent validity
The Spearman correlation of the PF total score with the 
JIA core set of outcome variables ranged from 0.3 to 0.5 
(median = 0.3). The PF total score best correlation was 
observed with the parent assessment of pain (r = 0.5, 
p < 0.001). For the HRQoL, the median correlation of the 
PhH with the JIA core set of outcome variables ranged from 
0.2 to 0.7 (median = 0.4), whereas for the PsH ranged from 
0.1 to 0.4 (median = 0.2). The PhH showed the best correla-
tion with the parent’s assessment of pain (r = 0.7, p < 0.001) 
and the PsH with the parent global assessment of well-being 
(r = 0.5, p < 0.001). The median correlations between the 
pain VAS, the well-being VAS, and the disease activity VAS 
and the physician-centred and laboratory measures were 0.3 
(0.2–0.4), 0.3 (0.2–0.4), 0.4 (0.2–0.5), respectively.
Discussion
In this study, the Castilian Spanish version of the JAMAR 
was cross-culturally adapted from the original standard Eng-
lish version with three forward and three backward transla-
tions. According to the results of the validation analysis, the 
Castilian Spanish parent and patient versions of the JAMAR 
possess satisfactory psychometric properties. The disease-
specific components of the questionnaire discriminated well 
between patients with JIA and healthy controls. This finding 
indicates that children with JIA adapt well to the conse-
quences of JIA.
The PF total score and the HRQoL scales proved to dis-
criminate between the different JIA subtypes with children 
with RF + poly-arthritis having a higher degree of disability 
and a lower quality of life.
Psychometric performances were good for all domains of 
the JAMAR with few exceptions: two PF items (“stretch out 
arms” and “bite a sandwich or an apple”) showed a lower 
item’s internal consistency. However, the overall internal 
consistency was good for all the domains.
Notably in the test–retest analysis, the HRQoL PhH and 
for the HRQoL PsH scores showed a poor reproducibility, 
whereas the PF ICC was very high. These findings are in 
contrast to those reported in most of the other JAMAR 
translations.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters were modest.
The results obtained for the parent version of the JAMAR 
are very similar to those obtained for the child version, 
which suggests that children are equally reliable proxy 
reporters of their disease and health status as their parents. 
The JAMAR is aimed to evaluate the side effects of medi-
cations and school attendance, which are other dimensions 
of daily life that were not previously considered by other 
HRQoL tools. This may provide useful information for inter-
vention and follow-up in health care.
In conclusion, the Castilian Spanish version of the 
JAMAR was found to have satisfactory psychometric prop-
erties and it is, thus, a reliable and valid tool for the multidi-
mensional assessment of children with JIA.
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